Allurion Presents at ASMBS Annual Meeting
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery
New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes
NATICK, Mass. -- June 11, 2024 – Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024.
Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. In comparison, studies show that patients treated with 12-month endoscopic intragastric balloons achieve 15.4%1 and 16.2%2 total body weight loss*. “We believe these findings underscore the potential of the Allurion Balloon to deliver superior outcomes to other intragastric balloons, approaching those of weight loss surgery,3,4 for patients seeking effective and safe weight loss solutions,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.
Evidence from multiple studies indicates that the Allurion Balloon—a procedureless, liquid-filled balloon—has a significantly lower intolerance rate compared to 12-month endoscopic balloons (1-3% vs 14.4%)5, with an overall serious adverse event rate that averages 10 times less than other liquid-filled balloons*.
Presentations also include data from a study analyzing 1,313 conversations from patients across 26 bariatric clinics in 12 countries and Coach Iris – Allurion’s AI-powered weight loss coach – assessing the safety, accuracy, and overall quality of a beta version released in 2023.
Conversations between patients and Coach Iris were reviewed against a unique framework developed in-house and recently presented at IFSO-EC. Named “FAST,” this framework is designed to evaluate and monitor the Fidelity, Accuracy, Safety, and Tone of Coach Iris. The text-based, human-like messaging received satisfaction scores of 84% on Fidelity, 79% on Accuracy, 89% on Safety, and 95% on Tone.
Presentations at ASMBS also include data on the impact of digital appetite tracking and eating behaviors in Allurion Balloon Program patients.
Details of the presentations are as follows:
Title: Consecutive 4-Month Swallowable Balloon Weight Loss Surpasses Results of a Single 12-Month Endoscopic Balloon and Approaches Weight Loss Surgery Results
Presenter: Roberta Ienca, M.D., Weight Management Center, Nuova Villa Claudia Clinic
Title: A Novel Conversational Agent Fine-Tuned for Bariatric Treatment Provides Safe and Accurate Patient Care: A Multi Country Study
Presenter: Martha Neary, M.Sc., Senior Manager Behavioral Medicine, Allurion
Title: Digital Tracking of Hunger and Fullness Enhances Awareness of Appetite, Food Choices and Portion Sizes in Patients with a Swallowable Gastric Balloon
Presenter: Zoe Griffiths, Bsc,. RD, Senior Director Behavioral Medicine, Allurion
For more information about ASMBS 2024, please visit: https://asmbsmeeting.com/about/
* The Allurion Balloon was not compared in head-to-head studies with any other gastric balloons.
Sources: 1. Obes Surg. 2024;34(1):176-182. doi:10.1007/s11695-023-06953-0; 2. Obes Surg. 2021;31(12):5342-5347. doi:10.1007/s11695-021-05729-8; 3. Obes Surg. 2021;31:3833–3847. https://doi.org/10.1007/s11695-021-05394-x); 4. ANZ J Surg. 2021;91(11):2443-2446. doi:10.1111/ans.17233; 5. Obes Surg. 2021;31(12): 5342-5347.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Balloon to deliver superior outcomes for patients seeking safe and effective treatment options. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.
###
Contacts
Global Media:
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com
Investors:
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion...
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
In a...
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion...
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to its Board of Directors
Mr. Johns has...
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight...
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
NATICK, Mass. -- June 5, 2024 -- ...
Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s
Company also announces first...
Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean...
Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including
First-Ever 3-Year...
Allurion Expands Virtual Care Suite to the United States
Virtual Care Suite (VCS) is now available to license...
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
NATICK, Mass. -- Jan. 29, 2024 -- Alluri...
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
Allurion...
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic...
Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4...
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion...
Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership
Company also announces addition...
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon
AUDACITY trial to support FDA...
Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023
Research highlights...
Allurion Featured at the 2023 International Bariatric Club
Oxford University World Congress
Congress...
Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach
Powered by GPT and Fine-Tuned...
Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress
New data includes...
Allurion Debuts as a Publicly Traded Company on the NYSE
Allurion to commence trading on August 2, 2023 on the...
Allurion Announces New Additions to Board of Directors and Executive Leadership Team
Serial healthcare...
Allurion Presents New Data at the 2023 ASMBS Annual Meeting Demonstrating Mean Weight Reduction of Over 20%
P...
Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered Weight Loss Program
...Allurion to Participate in the Jefferies Healthcare Conference
NATICK, Mass. -- May 30, 2023 – Allurion, a...
First Multi-Center Study Combining the Allurion Program with GLP-1 Therapy Presented at the European Congress...
Allurion Presents Findings from Landmark Study Evaluating Fully Remote Weight Loss Coaching Program
Proprietar...
Allurion Announces Premium Tiers for the Virtual Care Suite and Launch of Proprietary “My Daily Action” Bundle...
Allurion Announces Appointment of MIT Distinguished Professor for AI and Health and MacArthur “Genius” Fellow
...Allurion named “Champion Partner” of the World Obesity Federation and official sponsor of World Obesity Day...
Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination...
Allurion Technologies’ training awarded World Obesity Federation SCOPE accreditation
- Allurion’s gold...
Company reports 444% revenue growth from 2018 to 2021 and has also been named as one of MedTech Outlook’s Top...
- The world’s first and only procedureless gastric balloon receives approval from Brazilian Health...
New Delhi, 06 Sep 2022:
Allurion, a company dedicated to ending obesity, has launched the Allurion...
- Company launches the Allurion Iris™ Artificial Intelligence Platform and introduces Success Predictor, a...
Company announces approval of the Allurion Balloon in Canada, Mexico, Australia, and India where approximately...